Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies

Access Activity

Overview / Abstract:

Explore best practices in the management of tumor lysis syndrome associated with emerging cancer therapies. This activity, presented by Matthew S. Davids, MD, MMSc, Director of Clinical Research at Dana-Farber Cancer Institute, and Amy Goodrich, RN, BSN, MSN, CRNP-AC, Nurse Practitioner at Johns Hopkins Kimmel Cancer Center, will review plans to optimize prevention, recognition, and treatment, as well as discuss emerging therapies and monitoring strategies for patient care. Start the activity now!


Tumor lysis syndrome is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor cell death in which potassium, phosphate, and nucleic acids are released into the bloodstream (Baudon et al, 2016). This release of intracellular materials results in severe metabolic abnormalities such as hyperuricemia and hyperphosphatemia, which may cause acute renal injury, and hypokalemia and hypocalcemia, which may cause seizures, neuromuscular symptoms, and cardiac arrhythmias (Howard et al, 2016; Baudon et al, 2016). The occurrence of TLS may prevent or delay the administration of potentially life-saving chemotherapy (Dinnel et al, 2015). Furthermore, the kidney damage, heart failure, fluid retention, and neuromuscular and gastrointestinal effects caused by TLS may lead to reductions in chemotherapy dosing and alter the selection of cytotoxic agents (McBride & Westervelt, 2012). The most effective management strategy is prevention; however, despite appropriate prophylactic measures, approximately 3% to 5% of high-risk patients receiving chemotherapy are affected (Baudon et al, 2016). The overall mortality rate of patients with TLS is 15% (Jones et al, 2015).


Hematologist/oncologists, physician assistants, nurse practitioners, pharmacists, oncology nurses, and other health care professionals involved in the treatment of patients with cancer.


Upon completion of this activity, participants should be able to:

Assess the risk for TLS associated with emerging therapies for hematologic malignancies
Develop evidence-based management plans to optimize prevention, recognition, and treatment of TLS in patients with hematologic malignancies
Apply monitoring strategies to ensure adequate control of uric acid levels in patients diagnosed with TLS
Note: The learning objectives listed above apply to pharmacists, nurse practitioners, and registered nurses in addition to physicians.


Sep 30, 2022


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

Matthew S. Davids, MD, MMSc
Amy Goodrich, RN, BSN, MSN, CRNP-AC

Activity Specialities / Related Topics

Oncology / Cancer / Radiation Therapy

Keywords / Search Terms

i3 Health i3 Health i3 Health oncology, i3 Health, CNE, NCPD, free CNE, free NCPD Free CE CME Free CE CME, tumor lysis syndrome, TLS Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map